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to be 194.4 compared with 194.1 for the Alendronic acid group, which resulted 
in a difference of 0.33 QALYs. The total costs for the Zoledronic acid group and 
Alendronic acid group were LE 215,232 and LE 215,087 respectively. These costs 
yielded an ICER of LE 435 for the Zoledronic acid group. The odds ratio of zoledronic 
acid on vertebral & non-vertebral fractures was found to have the greatest impact 
on the results. ConClusions: Compared with our willingness-to-pay thresh-
old stated by world health organization for middle and lower income countries, 
Zoledronic acid is cost-effective; and most likely to result in an ICER lower than 
the threshold limit. Thus, the new treatment (Zoledronic acid) should be recom-
mended in the Ministry of health list.
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CoSt-EffECtivEnESS AnAlySiS of CAnACinuMAb in thE trEAtMEnt of 
PAtiEntS SuffEring froM SyStEMiC JuvEnilE idioPAthiC ArthritiS in 
ruSSiAn fEdErAtion
Yagudina R, Kulikov A, Pochuprina A
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To conduct the cost-effectiveness analysis (CEA) of canakinumab 
treatment group versus tocilizumab treatment group with systemic juvenile idi-
opathic arthritis (SJIA). Methods: CEA was used to compare canakinumab treat-
ment of patient group with previous inadequate response to tocilizumab versus 
tocilizumab treatment patient group which was subsequently switched to canaki-
numab. This analysis based on comparing treatments with usage of American 
College Rheumatology (ACR) criteria: ACR 30, 50, 70, 90 according to data of real 
clinical practice that were estimated within one year of therapy. Cost structure 
included following: drug treatment and administration costs, inpatient and out-
patient visits, correction of adverse events and required monitoring laboratory 
tests. Results: Cost-effectiveness ratios (CER) of tocilizumab and canakinumab 
treatment group was estimated for ACR 30 as 4,043,444 RUB/66,173 EUR and 
15,813,187 RUB/258,791 EUR, respectively; for ACR 50 as 4,043,444 RUB/66,173 EUR 
and 17,570,208 RUB/287,546 EUR, respectively; for ACR 70 as 7,188,345 RUB/ 117,641 
EUR and 19,284,375 RUB/315,599 EUR, respectively; ACR90 as 25,878,040 RUB/ 423,508 
EUR and 21,962,760 RUB/359,432 EUR, respectively. ConClusions: According to 
results of CEA costs per unit of effectiveness for treatment with canakinumab were 
higher in most cases. However, CER for ACR 90 as more effectiveness criteria was 
lower for canakinumab treatment group then in tocilizumab treatment patient 
group who were subsequently switched on canakinumab. It was determined that 
treatment with canakinumab was dominant method in comparison with tocili-
zumab treatment for ACR 90 criteria.
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objeCtives: To assess the cost-effectiveness ratio of tofacitinib when compared 
to alternative treatment strategies currently available for moderate to severe 
rheumatoid arthritis (RA) from the perspective of the Brazilian healthcare sys-
tem. Methods: A patient-level microsimulation model with a six-month length 
has been developed to measure the lifetime cost and quality-adjusted life-years 
(QALY) associated with RA treatment and disease progression. Patients’ outcome 
ranged based on the HAQ score. In the model, only severe adverse events were taken 
into consideration. The model compared treatment sequence with tofacitinibe with 
a comparator sequence without tofacitinibe in the patient care pathway following 
the 2014 Brazilian Therapeutic Guidelines for RA. The costs related to drug treat-
ment and to patient follow-up were taken into consideration. For such, the list price 
published by the Brazilian agency was used. Monitoring standards were defined 
by specialists and funded by using the list of procedures, orthoses, and prostheses 
from SUS [Brazilian Unified Health System] (SIGTAP) and the website for healthcare 
information (TABNET) from the Ministry of Health. The probability sensitivity analy-
sis was calculated having 50 first-order iterations and 500 second-order iterations, 
thus yielding a total of 25,000 iterations. An amount of BRL 81,667 was adopted 
as a limit of willingness to pay – equivalent to three times the national GDP per 
capita (2014). Results: In all scenarios, the treatment arm including tofacitinibe 
was shown to be dominant with lower costs and greater effectiveness – saving 
up to BRL 77,271.97. The probability sensitivity analysis (PSA) was also completed 
showing that tofacitinibe likely to be 52% more effective, 92% more economical and 
87% more cost-effective for one of the scenarios. ConClusions: The inclusion of 
tofacitinibe into the treatment strategy for moderate to severe RA is a dominant 
strategy for Brazilian healthcare system. These results were shown to be robust 
after completing PSA.
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CoSt-utility AnAlySiS of CErtolizuMAb PEgol for thE trEAtMEnt of 
ACtivE PSoriAtiC ArthritiS in grEECE
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objeCtives: To evaluate certolizumab pegol (CZP) relative to the other anti-TNFs, 
etanercept, infliximab, adalimumab and golimumab, and standard of care (SoC), 
among patients with active psoriatic arthritis (PsA), previously unresponsive to 
conventional disease-modifying antirheumatic drugs (cDMARD). Methods: A 
Markov model was used to simulate the lifetime progression of active PsA patients 
from treatment onset onwards. The model assumed that non-responders stop 
treatment and move to SoC. At treatment initiation, a 12- or 24-week treatment 
response assessment period was assumed. Long-term treatment withdrawal and 
patient mortality rates were obtained from the literature. SoC was defined as a 
mix of cDMARDs based on expert advice. Clinical efficacy was modeled in terms 
These results are in line with the Spanish clinical guidelines for RA which recom-
mend the use of tumor necrosis factor inhibitors as first-line treatment after failure 
with disease-modifying antirheumatic drugs.
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objeCtives: This analysis was designed to estimate the budget impact following 
the introduction of apremilast in the treatment of active psoriatic arthritis (PsA) for 
adult patients who have failed to respond to or are intolerant of disease-modifying 
antirheumatic drugs (DMARDs) in Spain. Methods: A budget impact model was 
developed to estimate healthcare costs for adults with PsA during a 3-year period 
from the NHS perspective. Target population was defined based on epidemiologi-
cal criteria; PsA prevalence (0.2%) and proportion of patients on biologic treatment 
(13.5%) were applied to national adult population statistics. Addition of apremilast 
to the therapeutic arsenal (adalimumab, etanercept, golimumab, infliximab, usteki-
numab) was explored. From the annual eligible population of PsA patients (N= 8,122), 
5% (n= 406), 11% (n= 893), and 18% (n= 1,462) were assumed to be treated with apre-
milast for the first, second, and third year, respectively. A local expert panel provided 
detailed resource consumption information. Total cost included drug acquisition 
based on drug doses from the summaries of product characteristics (ex-factory 
price with mandatory deduction), administration (parenteral drugs), and monitor-
ing costs. Unitary costs (€ , 2014) were obtained from national databases. Results: 
The total budget for the scenario without apremilast was € 101,104,837, € 101,082,349, 
and € 100,875,977 in the first, second, and third year, respectively. The pharmaceu-
tical cost represented 95% of this total cost. Following apremilast introduction, 
total budgets were reduced by € 1,244,342, € 2,735,080, and € 4,438,438 in the first, 
second, and third year, respectively. Incremental costs per patient comparing the 
scenario with apremilast vs. the scenario without apremilast were € −153.21 (−1.23%), 
€ −336.77 (−2.71%), and € −546.50 (−4.40%) in the first, second, and third year, respec-
tively. ConClusions: Apremilast treatment for PsA patients who have failed to 
respond to or are intolerant of DMARDs would imply a budget impact decrease on 
overall healthcare expenditure for the NHS.
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objeCtives: To determine the cost-effectiveness of apremilast for the treatment of 
active psoriatic arthritis for adult patients who failed to respond to or are intoler-
ant to disease-modifying antirheumatic drugs in Italy. Methods: A Markov state-
transition cohort model was adapted to the Italian setting to compare costs and 
quality-adjusted life-years (QALYs) from 2 treatment sequences: apremilast, adali-
mumab, etanercept, infliximab, and best supportive care (BSC) versus adalimumab, 
etanercept, infliximab, and BSC. The analysis time horizon was 40 years using a 
28-day cycle length. The perspective of the Italian National Health Service (NHS) was 
chosen. Treatment efficacy data (based on American College of Rheumatology [ACR] 
20 criteria and Psoriasis Area and Severity Index [PASI] 50/75/90 response rates) were 
derived from a network meta-analysis including 13 clinical trials. Resource use 
and unit costs were derived from Italian standard sources. Frequency of screening 
and testing for each treatment was derived from real-world data. Utility weights 
associated with PASI states were derived from a published study. A 3% discount rate 
was applied to costs and benefits. Both deterministic and probabilistic sensitivity 
analyses (PSA) were performed. Results: In the base case, the sequence including 
apremilast resulted in an incremental cost per QALY gained of € 32,263. Specifically, 
there was an increase of € 13,511 (€ 182,209 vs € 168,699) with an incremental gain of 
QALYs of 0.42 (9.57 vs 9.15) over 40 years. Base-case results were robust regarding 
changes in cost and efficacy data. Results were more sensitive to changes in utility 
weights, discount rates, and time horizon. The PSA confirmed that the apremilast 
sequence was cost-effective in the majority of the simulations at a willingness to 
pay of € 50,000 per QALY. ConClusions: This analysis suggests that the use of 
apremilast for the treatment of psoriatic arthritis may represent a cost-effective 
option for the Italian NHS.
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dECiSion AnAlySiS
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objeCtives: To evaluate from the Ministry of Health perspective, over a five-year 
period, the cost-effectiveness of using zoledronic acid 5mg compared to that of 
alendronic acid in the treatment of osteoporosis in postmenopausal Egyptian 
patients. Methods: A Markov model with five mutually exclusive health states 
(Well, hip fracture, spine (vertebral) fracture, wrist (non-vertebral) fracture, and 
death) was developed.The transition probabilities between the health states 
were derived from a previously published source. Health state utilities and major 
adverse events were obtained from published sources. Direct medical costs were 
obtained from the Ministry of health list. Costs and effects were discounted at 
3.5% annually. One way sensitivity analyses were conducted. Results: Across the 
overall population, the total QALYs of the Zoledronic acid group were estimated 
